Document is current
Any future updates will be listed below
-
Authors
Pesini, Cecilia
Gil-Bellido, Mario
S Millan, Lorena
Oñate, Carmen
Calvo-Pérez, Adanays
Santiago, Llipsy
Iglesias, Eldris
Bernal, Jorge Paúl
Araujo-Voces, Miguel
Paz Artigas, Laura
García-Martínez, Laura
Roig, Francisco J
Movilla Meno, Nieves
Garcia-Aznar, José Manuel https://orcid.org/0000-0002-9864-7683
Menéndez-Jandula, Bárbara
Olave, María Teresa
Azaceta Reinares, Gemma
Garrote, Marta
Alvarez-Larrán, Alberto
Gálvez, Eva M
Sánchez Martínez, Diego
Arias, Maykel A
Pardo, Julian https://orcid.org/0000-0003-0154-0730
Ramirez-Labrada, Ariel https://orcid.org/0000-0002-3888-7036
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03222609 at ClinicalTrials.govnct06034002 at ClinicalTrials.govDocuments that mention this clinical trial
Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms
https://doi.org/10.1136/jitc-2025-012706
nct05936359 at ClinicalTrials.govDocuments that mention this clinical trial
Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms
https://doi.org/10.1136/jitc-2025-012706
nct06150157 at ClinicalTrials.govDocuments that mention this clinical trial
Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms
https://doi.org/10.1136/jitc-2025-012706
Documents that mention this clinical trial
Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms
https://doi.org/10.1136/jitc-2025-012706
- License Information
